Risperidone: 7 agencies, 1995–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 31.2 years separate the first record, 1 May 1995 at PHARMAC (New Zealand), from the most recent, 2026 at PBAC (Australia).
HAS (France) changed its position: recommended on 16 Mar 2016, not recommended by 11 Jul 2018.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 4 of 22 records date from 2023 or later.
6 distinct indication wordings are recorded for risperidone by the agencies that label one in English (AWMSG, PBAC and SMC).
5 of these 22 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PHARMAC (New Zealand) was first to assess risperidone, on 1 May 1995; TLV (Sweden) did not open a file until 28 Apr 2023 — an unusually long tail of 27.9 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 16 years in total.
4 of the 7 agencies here assessed risperidone more than once, HAS (France) most often at 8 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for risperidone.
The full ledger for risperidone reads 12 recommended, 6 other, 2 not recommended and 1 advice, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2024 | Schizophrenia | Recommended | source |
| TLV (Sweden) | 28 Apr 2023 | Okedi ingår i högkostnadsskyddet | general subsidy | source |
| AWMSG (Wales) | 4 Apr 2022 | Treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone | outside AWMSG criteria | source |
| HAS (France) | 11 Jul 2018 | Listing (Transparency Committee) | SMR insufficient · ASMR V | source |
| CONITEC (Brazil) | 14 Jan 2016 | Comportamento agressivo em adultos com transtorno do espectro do autismo (TEA) | incorporated into SUS | source |
17 further decisions for risperidone, across 5 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 7 further source documents.
Related molecules
- aripiprazole — same ATC class N05A — Psycholeptics
- paliperidone — same ATC class N05A — Psycholeptics
- olanzapine — same ATC class N05A — Psycholeptics
- quetiapine — same ATC class N05A — Psycholeptics
- lurasidone — same ATC class N05A — Psycholeptics
- droperidol — same ATC class N05A — Psycholeptics
Coverage: 22 decisions for risperidone from 7 agencies, 1995 to 2026. Data to 7 Sep 2026. ATC class N05A — Psycholeptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.